The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal ...

Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide ...

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...

Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide ...

COPENHAGEN, April 24 (Reuters) - Danish biotechnology company Zealand Pharma (ZELA.CO), opens new tab said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss ...

Zealand Pharma (ZLDPF) announces the implementation of long-term incentive programs for 2025 for Zealand Pharma’s Board of Directors, Corporate ...

Singh will lead the discovery and clinical translation of peptide medicines, investing in new technologies, including data and computational science.

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025 Copenhagen, Denmark, April 19, 2025 – Zealand Pharma A ...